Pharmaceutical Technology, Dec 2, 2012 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Dec 2, 2012
Special Report
Job Security
By Amy Ritter
Annual employment survey results show greater confidence in the pharma industry.
Special Features
Tracking the Supply Chain
By Adeline Siew, PhD
As the battle against counterfeits gains momentum, PharmTech speaks to Mark Davison, CEO of Blue Sphere Health, and Craig Stobie, global life sciences sector manager at Domino Printing Sciences, about the challenges involved.
Harmonizing Global Efforts Against Counterfeits
By Janice Kite
In addition to globalisation, high financial rewards and low penalties for counterfeiters are contributing to the rise in fake medicines.
Innovation in a Leading Disease Target: Alzheimer's
By Angie Drakulich
An interview with Eric M. Parker, Ph.D., Executive Director and Neuroscience Site Lead, Merck Research Laboratories, about the Merck BACE team's winning research.
Harnessing the Power of Fingerprinting Technologies
By Ian T. Campbell , Detlef Beckers
A few years ago, drug criminals would put all their efforts into matching packaging and labeling, or manufacturing good-looking fake materials. Today, criminals are capable of much more.
Pharma Innovation
By Angie Drakulich
A look at the year's leaders in innovation strategy, including the top bio/pharmaceutical companies and award recipients from AAPS, PhRMA, and CPhI.
Collaborating to Protect the Supply Chain from Counterfeiters
By Adeline Siew, PhD
Adeline Siew PharmTech speaks to Lynne Byers and Brian Johnson about Rx-360's initiatives to protect patient safety.
Pharma Ingredients
The Class of 2012 for New Molecular Entities and Biologics
By Patricia Van Arnum
As 2012 comes to a close, Pfizer leads among Big Pharma companies for FDA approvals of new molecular entities and biologics.
Peer-Reviewed Research
Development and Commercialization of a Novel Modified Release Tablet Technology
By Kevin D. Altria , James Taylor
GlaxoSmithKline recently developed a novel technology for the formulation of modified-release tablets. The authors describe the route from development to commercialization.
From The Editor
When Disaster Strikes at Home
By Angie Drakulich
PDA's strategic plan calls for maintaining valuable and effective relationships with global regulators.
Agent-in Place
Mice on a Mission
By Control, a senior compliance officer
To ensure the accuracy of scientific testing, protect the subjects to avoid data contamination.
Regulatory Watch
Health Policy Challenges for Obama Administration
By Jill Wechsler
White House and Congress likely to struggle over funding for bio/pharmaceutical regulation.
Statistical Solutions
Time to Revise ICH Q9
By Lynn D. Torbeck
A change in terminology could emphasize patient protection.
A Lifecycle Approach to Optimizing Cleaning Systems
By Andrew Wong , Cody Shrader
Clean-in-place systems should be optimized during design and commissioning and after validation.
Outsourcing Outlook
Acquisitions Reshape the Bio/Pharm Services Industry
By Jim Miller
The quest to build critical mass and broaden capabilities has been a key factor in deal-making.
Patents and Postapproval Batch Testing
By Kevin Murphy , Andrew Nason
Can postapproval FDA filings immunize pharma companies from patent lawsuits?
In the Field
Report from South Korea
By Jane Wan
Domestic companies are changing their business models in response to recent drug price cuts.
In the Spotlight
In the Spotlight
New product reviews for December 2012.


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here